Studies on ACC models have indicated that ATR inhibitors may have some benefit in ACC as ATR is downstream of MYB [48], paired with data from preclinical studies in other tumour types that have demonstrated that treatment with ATR inhibitors in TP53-mutant tumours results in increased radiotherapy and chemotherapy sensitisation [42], providing a rationale for the enrolling patients whose tumours harbour TP53 mutations in trials such as NCT03669601. Here, ATR is linked to neoplasm.